Exelixis

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Exelixis and other ETFs, options, and stocks.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic.

CEO

Michael M. Morrissey

CEOMichael M. Morrissey

Employees

1,077

Employees1,077

Headquarters

Alameda, California

HeadquartersAlameda, California

Founded

1994

Founded1994

Employees

1,077

Employees1,077

EXEL Key Statistics

Market cap

16.14B

Market cap16.14B

Price-Earnings ratio

20.27

Price-Earnings ratio20.27

Dividend yield

—

Dividend yield—

Average volume

2.18M

Average volume2.18M

High today

—

High today—

Low today

—

Low today—

Open price

$64.85

Open price$64.85

Volume

0.00

Volume0.00

52 Week high

$65.59

52 Week high$65.59

52 Week low

$36.00

52 Week low$36.00

Stock Snapshot

Exelixis(EXEL) stock is priced at $65.11, giving the company a market capitalization of 16.14B. It carries a P/E multiple of 20.27.

During the trading day, Exelixis(EXEL) stock saw an opening price of $64.85, a peak of —, and a bottom of —.

Trading volume for Exelixis(EXEL) stock has reached 0, versus its average volume of 2.18M.

The stock's 52-week range extends from a low of $36.00 to a high of $65.59.

EXEL News

Simply Wall St 1d

Exelixis Faces An FDA Delay, Is The Stock Fully Valued? - Simply Wall Street

...

The Motley Fool 3d

Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy

Exelixis (EXEL -1.19%) has crushed the broader market this year, with its shares climbing 49%. However, the drugmaker recently hit a roadblock. The U.S. Food an...

Simply Wall St 3d

How Earnings Expectations At Exelixis Has Changed Its Investment Story

Exelixis recently attracted attention after analysts highlighted expectations for higher quarterly revenue and earnings per share, supported by ongoing demand f...

Analyst ratings

58%

of 19 ratings

Buy

31.6%

Hold

57.9%

Sell

10.5%

More EXEL News

Simply Wall St 4d

Exelixis Stock May Look Like A Bargain On FDA Review Delay

has seen its stock price climb sharply in recent years, which puts fresh attention on whether that kind of move is supported by its earnings power today. With t...

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Sterling Infrastructure

Argan

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.